ATTR-CM Scores Get Mixed Results for Flagging Risk in Diverse Patients https://t.co/HFnvFkf19z
Thank you @medpagetoday for highlighting the great work led by
@GGreenbergMD@MonteHeart
Key points 🔑
➡️ Only 2/3 of patients had follow-up lipid testing
➡️ Of these, only 1/2 met LDL-C goals
➡️ Female and Black patients we less likely to attain LDL-C goals
⭐️ We have work to do! 🫀🏥🩺
Disparities in Achieving LDL-C Goals After Revascularization in a Diverse Real-World Cohort
Check out our article! We need to improve lipid testing and treatment for our ASCVD patients!
@CardioMDPhD@danilorenzatti@DrMarthaGulati@DrMichaelShapir
https://t.co/LODj4Rxvh6
Heart disease is the #1 cause of death worldwide.
On @BronxnetTV, @CardioMDPhD explains that many people live with undetected risk factors like high blood pressure and diabetes. Early detection is key—regular screenings and heart-healthy habits can help prevent heart disease.
Excited to share the results of our work, which will help extend the use of diagnostic tools for ATTR-CM to more diverse patient populations. Grateful for your mentorship @CardioMDPhD !
@JCardFail@MonteHeart@MontefioreNYC